STOCK TITAN

Fulcrum Therapeutics (FULC) Stock Price, News & Analysis

FULC NASDAQ
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
33 252 sessions, November 20, 2025 to November 20, 2026
Largest daily move
-51.1% close of June 2, 2026
1-year change
-66.6% closing prices, November 20, 2025 to November 20, 2026
1-month change
-0.8% closing prices, October 20, 2026 to November 20, 2026

Company Description

Fulcrum Therapeutics, Inc. (Nasdaq: FULC) is a clinical-stage biopharmaceutical company that focuses on developing small-molecule medicines for patients with genetically defined rare diseases in areas of high unmet medical need. According to the company’s public disclosures, Fulcrum concentrates on targets that can modulate gene expression, aiming to address the known root cause of gene mis-expression in these disorders.

Fulcrum’s lead clinical program is pociredir, described as an investigational oral, once-daily small molecule designed to increase expression of fetal hemoglobin (HbF) for the treatment of sickle cell disease (SCD). The company states that pociredir is an inhibitor of Embryonic Ectoderm Development (EED) discovered using its proprietary discovery technology. By inhibiting EED, pociredir is intended to downregulate key fetal globin repressors, including BCL11A, which in turn is designed to increase HbF levels in patients with SCD.

Fulcrum reports that pociredir is being evaluated in the PIONEER Phase 1b clinical trial in adults with severe sickle cell disease. Company communications describe PIONEER as an open-label, dose-escalation study assessing safety and efficacy, with secondary endpoints that include HbF induction, hemolysis, and anemia, and exploratory endpoints that include globin gene expression, percentage of F-cells, and incidence of vaso-occlusive crises (VOCs). Initial data from multiple dose cohorts, including 12 mg and 20 mg, have been highlighted by Fulcrum as showing proof-of-concept for HbF induction and associated changes in markers of hemolysis and anemia, with pociredir described as generally well-tolerated through several months of exposure in adults with SCD.

In addition to its lead program, Fulcrum states that it uses proprietary technology to identify drug targets that can modulate gene expression. This platform-based approach underpins its focus on genetically defined rare diseases, where specific gene-regulation mechanisms can be linked to disease biology. The company has also discussed a program involving calmodulin pathway modulators for the potential treatment of bone marrow failure syndromes, and has presented preclinical data on an EED inhibitor candidate, FTX-6274, in oncology models, indicating that its research efforts extend beyond sickle cell disease into other hematologic and genetic conditions.

Fulcrum’s recent public updates emphasize its concentration on genetically defined rare diseases, with sickle cell disease as the primary clinical focus. SCD is described in company materials as a genetic disorder of red blood cells caused by a mutation in the HBB gene, leading to abnormal hemoglobin, sickle-shaped red blood cells, and serious clinical consequences such as anemia, pain, and organ complications. By targeting fetal hemoglobin induction, Fulcrum’s approach with pociredir is positioned around a mechanistic strategy that seeks to counteract the underlying effects of the sickle hemoglobin mutation.

The company is listed on The Nasdaq Global Market under the symbol FULC, as indicated in its SEC filings. Fulcrum has also reported that pociredir has received FDA Fast Track designation and Orphan Drug Designation for the treatment of sickle cell disease. These regulatory designations, as described in the company’s communications, are intended to support the development of therapies for serious conditions and rare diseases.

Fulcrum’s public filings and press releases also describe its use of capital to support research and development, including funding clinical trials, regulatory submissions, discovery activities, additional preclinical research and development of product candidates, and enhancement of its platform. The company has accessed the public equity markets through underwritten offerings of common stock and pre-funded warrants, as documented in its SEC reports, to finance these activities and general corporate purposes.

Corporate materials identify Fulcrum Therapeutics as based in Cambridge, Massachusetts. As a clinical-stage company, Fulcrum focuses on advancing its investigational therapies through early- and mid-stage clinical development, while also maintaining discovery and preclinical programs that apply its gene-expression modulation technology to additional rare disease targets.

Business focus and therapeutic strategy

Fulcrum’s stated strategy centers on small-molecule modulation of gene expression in genetically defined rare diseases. Rather than replacing genes, the company’s approach, as described in its communications, is to identify and drug targets that can adjust the expression of disease-relevant genes. Pociredir exemplifies this strategy by aiming to increase fetal hemoglobin through inhibition of EED and downregulation of repressors such as BCL11A.

In company disclosures, Fulcrum highlights that increasing HbF in sickle cell disease is a scientifically grounded strategy, with higher HbF levels associated with reductions in vaso-occlusive crises and improvements in markers of red blood cell health. The PIONEER trial results shared by Fulcrum include changes in HbF levels, F-cell percentages, markers of hemolysis, and hemoglobin concentration, which the company uses to characterize the pharmacodynamic profile of pociredir.

Pipeline and research areas

Beyond pociredir, Fulcrum has communicated work on a calmodulin pathway modulator program for potential treatment of bone marrow failure syndromes, such as Diamond-Blackfan anemia and related conditions. It has also reported preclinical data for FTX-6274, an oral EED inhibitor candidate evaluated in castration-resistant prostate cancer models. These efforts indicate that the company’s gene-expression modulation platform is applied to both hematologic and oncologic indications, although pociredir in SCD remains the lead clinical program described in its recent updates.

Regulatory and corporate status

SEC filings show that Fulcrum’s common stock is registered under Section 12(b) of the Securities Exchange Act and trades on The Nasdaq Global Market under the symbol FULC. The company holds annual meetings of stockholders, submits advisory votes on executive compensation, and discloses the selection of its independent registered public accounting firm, as reflected in its annual meeting Form 8-K. Fulcrum has also filed current reports describing financial results, clinical data updates, and capital-raising transactions, including an underwriting agreement for a public offering of common stock and pre-funded warrants.

Stock Performance

$3.68
-0.27%
-0.01
After hoursChange vs the $3.69 closeLast updated: at
-66.6%
Performance 1 year
$281.1M
76.4M
Shares outstanding As of November 8, 2026.

Fulcrum Therapeutics (FULC) closed at $3.69 on November 20, 2026. Over the past 12 months, the price has lost 66.6%.

See what a $1,000 investment in FULC would be worth today

Average down calculator for FULC

FULC Metrics & Rankings

Price returns through November 20, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

Fulcrum Therapeutics has 10 recent news articles. Of the recent coverage, 3 articles coincided with positive price movement and 7 with negative movement. Key topics include acquisition, earnings, management, conferences, earnings date. View all FULC news →

Financial Highlights

Fulcrum Therapeutics reported operating income of -$84.8M in FY2025, and net income was -$74.9M. Diluted earnings per share stood at -$1.18. The company generated -$60.1M in operating cash flow. The current ratio was 27.40, measuring current assets divided by current liabilities.

$0
Revenue (FY2025)
-$74.9M
Net Income (FY2025)
-$60.1M
Operating Cash Flow

Upcoming Events

JAN
05
January 5, 2027 Corporate

25% option vesting

25% of 30,400 inducement options vest (grant price $10.84, effective 2026-01-05)
JAN
05
January 5, 2027 - January 5, 2030 Corporate

Quarterly vesting period

Remaining 6.25% vests quarterly over the following 12 quarters, completing full vesting
FEB
02
February 2, 2027 Corporate

25% vests

First-anniversary vesting of 25% of 70,000 options; grant assumed 2026-02-02
FEB
02
February 2, 2027 - February 2, 2030 Corporate

Quarterly vesting period

6.25% vests quarterly for 12 quarters following first anniversary; completes 2030-02-02
MAR
02
March 2, 2027 - March 2, 2030 Corporate

Option vesting period begins

34,000 inducement options vest: 25% at 1yr, then 6.25% quarterly for 12 quarters
MAY
04
May 4, 2027 Corporate

First vesting (25%)

25% of 55,500 inducement options vest per plan; exercise price $7.02; granted under 2022 Inducement Stock Incentive Plan.
FEB
02
February 2, 2030 Corporate

Options fully vested

All 70,000 options fully vested after four years from assumed start 2026-02-02
MAY
04
May 4, 2030 Corporate

Full vesting completion

Remaining 75% vests over 12 quarterly installments; 55,500 options fully vested by this date; exercise price $7.02.
JAN
05
January 5, 2036 Corporate

Option expiration

10-year term expiration of inducement options granted 2026-01-05 (exercise price $10.84)
MAR
02
March 2, 2036 Corporate

Option expiration date

10-year term ends for 34,000 options; exercise price $7.81 per share
MAY
04
May 4, 2036 Corporate

Options expire

10-year term expires for the 55,500 inducement options if unexercised; exercise price $7.02; granted under Nasdaq rule.

Fulcrum Therapeutics has 11 upcoming scheduled events. The next event, "25% option vesting", is scheduled for January 5, 2027 (in 44 days). Investors can track these dates to stay informed about potential catalysts that may affect the FULC stock price.

Short Interest History

Last 12 Months

Short interest in Fulcrum Therapeutics (FULC) currently stands at 6.4 million shares, down 4.7% from the previous reporting period, representing 8.7% of the float. Since November 2025, short interest has increased by 69.2%.

Days to Cover History

Last 12 Months

Days to cover for Fulcrum Therapeutics (FULC) currently stands at 4.8 days. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has increased by 22.3%. Across the settlements charted above, it has ranged from 1.0 to 19.8 days.

FULC Company Profile & Sector Positioning

Fulcrum Therapeutics (FULC) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing FULC often look at related companies in the same sector, including Relmada Therapeutics, Inc. (RLMD), Altimmune, Inc. (ALT), Benitec Biopharma Inc. (BNTC), Galectin Therapeutics Inc. (GALT), and Kyverna Therapeutics, Inc. (KYTX). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate FULC's relative position within its industry.

Frequently Asked Questions

The current stock price of Fulcrum Therapeutics (FULC) is $3.68 in after-hours trading as of November 20, 2026.

The market cap of Fulcrum Therapeutics (FULC) is approximately $281.1M. Learn more about what market capitalization means .

The FY2025 revenue of Fulcrum Therapeutics (FULC) is $0, from its most recent completed fiscal year.

The FY2025 net income of Fulcrum Therapeutics (FULC) is -$74.9M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Fulcrum Therapeutics (FULC) is -$1.18 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Fulcrum Therapeutics (FULC) is -$60.1M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The current ratio of Fulcrum Therapeutics (FULC), current assets divided by current liabilities, was 27.40 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The operating income of Fulcrum Therapeutics (FULC) is -$84.8M for FY2025, its most recent completed fiscal year. Learn about operating income.